Latest Conference Articles

Neratinib Shows Promise in HER2-Mutated Cancers

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

Dr. Stupp on Final Results for TTFields Added to Chemo in Glioblastoma

Roger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.

Dr. Neelapu on Primary Results of the ZUMA-1 Trial in NHL

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

ACCC Speaker Says Drug Pricing Reform May Gather Momentum

Jessica Turgon, MBA, of ECG Management Consultants says that changes in 340B Drug Pricing Program rules and the CMS physician payment formula are possible.

Clarifying the Role of Oncology Nurse Navigators

Tricia Strusowski, MS, RN, discusses the role of the oncology nurse navigator and how these staffers can help meet outcome and quality standards set by the CMS's OCM.

Dr. Crews Reflects on the Achievements of the ACCC During Her Presidency

The outgoing president of the Association of Community Cancer Centers, Jennie Crews, MD, MMM, FACP reflects on her time as president and the achievements the ACCC made.

Federal Healthcare Policy Is Front and Center at CANCERSCAPE Conference

While at the annual CANCERSCAPE meeting of ACCC, Kavita Patel, MD, MS, comments on uncertainy in the healthcare environment and key policy to be aware of.

Dr. Presant on Adjusting Clinical Trials to Value-Based Care

Cary Presant, MD, FACP, FASCO, City of Hope Medical Center, discusses clinical trials and value-based care.

ACCC Calls for Vigilance Despite Repeal Failure

The Republican-led Affordable Care Act repeal and replace effort has the potential to be revived, but majority leaders may not want to risk further political capital in a battle that could go against them, speakers said at this year's Association of Community Cancer Centers' CANCERSCAPE annual conference.

Dr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast Cancer

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Neoadjuvant Therapy Fundamental in TNBC and HER2+ Breast Cancer

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

Age, Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

Expert Examines Clues to Deploying Immunotherapy in Breast Cancer

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

Big Data May Guide Future Treatment Decisions

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

CDK4/6 Inhibitors Changing Practice in Advanced Breast Cancer

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Emerging Data Could Show True Benefit of Y-90 Radioembolization in Liver-Metastatic CRC

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

Expert Discusses Promise of Immunotherapy in TNBC

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

Sequencing, Patient Selection Among Challenges in GI Cancers

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

Dr. Piccart on the Importance of De-Escalation in Early Breast Cancer

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Combination Approaches Combat Resistance to Endocrine Therapy in HR+ Breast Cancer

Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.

Ribociclib Response Unaffected by Prior Treatment

Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.

Novel Approaches, Individualization Needed in mCRC

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

Combinations Show Promise in Overcoming Resistance to HER2-Targeting Therapy

C. Kent Osborne, MD, discusses current strategies for overcoming resistance to HER2-targeting agents in early breast cancer today.

Immunotherapy, Emerging Agents Offer Hope in GI Cancers

Johanna Bendell, MD, discusses the promising impact of immunotherapy and other emerging agents in the field of gastrointestinal cancer.

Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast Cancer

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

Immunotherapy AXAL Tops Survival Mark in Cervical Cancer

An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.

Maintenance Chemotherapy Yields No OS Benefit in Ovarian Cancer

Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.